Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0
članak: 1 od 6  
Back povratak na rezultate
Serbian Journal of Experimental and Clinical Research
2020, vol. 21, br. 1, str. 51-58
jezik rada: engleski
vrsta rada: izvorni naučni članak
objavljeno: 02/07/2020
doi: 10.2478/SJECR-2018-0010
Troškovi lečenja teškog pogoršanja HOBP-a u Srbiji
aUniverzitet u Kragujevcu, Medicinski fakultet
bPharmaceutical Chamber of Serbia, Belgrade
cPharmaceutical Chamber of Federation of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina

e-adresa: rpavlovic@medf.kg.ac.rs

Sažetak

Glavni cilj ovog istraživanja je bio da se utvrdi i prikaže ekonomski aspekt ozbiljnih pogoršanja HOBP-a koje zahtevaju hospitalizaciju i razlike u troškovima lečenja između grupe pacijenata čestih egzacerbatora - sa najmanje dva pogoršanja tokom jedne godine i grupe pacijenata sa jednim pogoršanjem. Naši rezultati sugerišu da značajno više resursa treba potrošiti za lečenje pacijenata sa najmanje dve hospitalizacije tokom jedne godine i to za upotrebu lekova koji prvenstveno utiču na respiratorni sistem (kortikosteroidi, p = 0.013, teofilin, p = 0.007 ), ukupan boravak u bolnici (31336.68 ± 19140 dinara u odnosu na 23650.15 ± 14956.0 dinara, ili izraženo u eurima 517.53 ± 316.1 EUR/ 390.59 ± 247 EUR, p = 0.002), boravak u poluintenzivnoj jedinici, 12875.35 ± 20742.54 dinara naspram 4310.62 ± 9779.78 dinara, odnosno 212.64 ± 342.57 EUR /71.19 ± 161.51 EUR (p = 0.006). Posmatrajući ukupan broj dana u bolnici, novac za lekove, korišćeni materijal i pružene usluge, značajno više sredstava je utrošeno za lečenje pacijenata iz grupe čestih egzacerbatora, 80034.1 ± 36823.7 RSD / 1321, 78 ± 608.15EUR, naspram 69425.5 ± 34083.1 RSD / 1146.58 ± 562.89 EUR za grupu pacijenata sa jednom egzacerbacijom (p = 0.039). Može se zakljućiti da će značajno više sredstava biti potrošeno u lečenju pogoršanja pacijenata koji pripadaju grupi čestih egzacerbatora. Ovi pacijenti će boraviti duže u bolnici ili u jedinici poluintenzivne nege, upotrebiće se značajno više lekova koji se prvenstveno koriste u lečenju respiratornog sistema, a samim tim će i troškovi biti značajno veći.

Ključne reči

HOBP; teško pogoršanje; hospitalizacija; troškovi

Reference

Novododat članak: provera, normiranje i linkovanje referenci u toku.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V. et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380(9859), 2095-2128. DOI: 10.1016/S0140-6736(12)61728-0
Mathers CD, Loncar D. (2006). Projections of Global Mortality and Burden of Disease from 2002 to 2030. Plos Medicine. 3(11), 2011-2030. DOI:10.1371/journal. pmed.0030442
Blasi F, Cesana G, Conti S, Chiodini V, Aliberti S, Fornari C & Mantovani LG. (2014 ). The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 9(6), 1-8. DOI:10.1371/journal.pone.0101228
Wan E, De Meo D, Hersh C, Shapiro S, Rosiello R, Sama S, Fuhlbrigge A, Foreman M & Silverman E. (2011). Clinical predictors of frequent exacerbations in subjects with 6 severe chronic obstructive pulmonary disease (COPD). Respir Med. 105(4), 588-594. DOI: 10.1016/j.rmed.2010.11.015
Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF & Wedzicha JA. (2010). Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 363(12), 1128-1138. DOI:10.1056/NEJMoa0909883
Parikh R, Shah TG & Tandon R. (2016). COPD exacerbation care bundle improves standard of care, length of stay, and readmission rates. Int J Chron Obstruct Pulmon Dis. 11(1), 577-583. DOI: 10.2147/COPD.S100401
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F & Galvn L. (2015). Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study. BMC Fam Pract. 16:173. DOI: 10.1186/s12875-015-0387-6
Guarascio AJ, Ray SM, Finch CK & Self TH. (2013 ). The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 5, 235-245. DOI: 10.2147/CEOR.S34321
Lazic Z, Gajovic O, Tanaskovic I, Milovanovic D, Atanasijevic D & Jakovljevic M. (2012 ). GOLD Stage Impact on COPD Direct Medical Costs in the Elderly. Health Behav & Pub Health. 2(3), 1-7
Menn P, Leidl R & Holle R. (2012). A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 30(9), 825-840. DOI: 10.2165/11591340-000000000-00000
Hoogendoorn M, KappelhoffBS, Overbeek JA, Wouters EF & Rutten-van Mölken MP. (2012). Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Neth J Med. Review. 70(8), 357-364
Ornek T, Tor M, Altın R, Atalay F, Geredeli E, Soylu O & Erboy F. (2012 ). Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int J Med Sci. 9(4), 285-90. DOI: 10.7150/ijms.4039
Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M & Blum S. (2011). Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 14(3), 315-323. DOI: 10.3111/13696998.2011.576295
Abudagga A, Sun SX, Tan H, Solem CT. (2013). Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis. 8, 175-85. DOI: 10.2147/COPD.S40437
Global Initiative for Chronic Obstructive Lung Disease. (2014). Global Strategy for the Diagnosis. Management and Prevention of Chronic Obstructive Pulmonary Disease. Available on: http://www.goldcopd.org
World Health Organization. Chronic obstructive pulmonary disease (COPD).(2011). Available on: http:// www.who.int/respiratory/copd/en
Valente S, Pasciuto G, Bernabei R & Corbo GM. (2010). Do we need different treatments for very elderly COPD patients? Respiration. 80(5), 357-368. DOI: 10.1159/000320221
Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. (2015). Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 10, 95-109. DOI: 10.2147/COPD. S54473
Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. (2012). Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 7, 757-764. DOI: 10.2147/ COPD.S36997
Doos L, Uttley J, Onyia I, Iqbal Z, Jones PW & Kadam UT. (2014). Mosaic segmentation, COPD and CHF multimorbidity and hospital admission costs: a clinical linkage study. J Public Health (Oxf ). 36(2), 317-324. DOI: 10.1093/pubmed/fdt070
Halpin DM & Miravitlles M. (2006). Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 3(7), 619-623. DOI: 10.1513/pats.200603-093SS
Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA & Coultas DB. (2000). Health care utilization in chronic obstructive pulmonary disease. A casecontrol study in a health maintenance organization. Arch Intern Med. 160(17), 2653-2658. DOI:10.1001/ archinte.160.17.2653
Cazzola M, Bettoncelli G, Sessa E, Cricelli C & Biscione G. (2010). Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 80(2), 112-119. DOI: 10.1159/000281880
Mannino DM1, Watt G, Hole D, Gillis C, Hart C, Mc-Connachie A, Davey Smith G, Upton M, Hawthorne V, Sin DD, Man SF, Van Eeden S, Mapel DW, Vestbo J. (2006). The natural history of chronic obstructive pulmonary disease. Eur Respir J. 27(3), 627-643. DOI: 10.1183/09031936.06.00024605
Säynäjäkangas O, Kinnunen T, Tuuponen T, Keistinen T. (2004). Length of stay and interval to readmission in emergency hospital treatment of COPD. Age Ageing. 33(6), 567-570. DOI: 10.1093/ageing/afh188
Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A & White PT. (2015). Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. Int J Chron Obstruct Pulmon Dis. 10, 603-611. DOI: 10.2147/COPD. S77092
Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A & Papaioannou A. (2014). Prediction of hospitalization stay in COPD exacerbations: the AE-COPD-F score. Respir Care. 59(11), 1679-1686. DOI: 10.4187/respcare.03171
Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. (2012). Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 7, 183-199. DOI: 10.2147/COPD.S29820